Biotechnology firm, Kuros Biosurgery declared that it has received a notice of allowance for its European patent application 00910049 from the European Patent Office.
The patent application is an important part of Kuros’s extensive range of patents and applications developed to safeguard the company’s artificial biomaterial (matrix) technologies and product candidates that use these technologies. This unique synthetic biomaterial platform is a major source of advanced products, which will be vital for the future development of the company.
The currently allowed patent application encompasses Kuros` in-house method for producing biomaterials by nucleophilic addition mechanism beginning from functionalized precursor components like PEGs. It covers the synthetic matrix-based biomaterial, its manufacturing process, tools for delivery and numerous applications.
Kuros is producing a broad range of biomaterial and biomaterial-bioactive products. Two dissimilar matrix technology platforms, fibrin and synthetic matrices, are the basis of the product candidates.
Kuros’ KUR-023, a synthetic matrix technology-based dural sealant, is a sophisticated product candidate, which is now undergoing clinical study in order to get CE marking in Europe.
Kuros’ KUR-113 and KUR-111, sophisticated products developed by the fibrin matrix technology, have shown encouraging results during the Phase II trials for tibial shaft fractures and tibial plateau fractures, respectively.